HPV Infects Many Body Sites
HPV is not only a cervical cancer virus.
- 4: Body sites at risk (beyond the cervix alone)
- 200+: HPV types identified (genetically distinct strains)
- 12: High-risk oncogenic types (cause most HPV cancers)
- ~46,000: US HPV cancers yearly (diagnosed across all sites)
One virus, many tissues
HPV infects any moist squamous epithelium in the body.
Men are also at risk
Men carry no cervix but still face HPV cancer risk.
Shared viral mechanism
E6 and E7 oncoproteins drive cancer at every site.
Oropharyngeal Cancer Is Rising In Men
HPV now causes more throat cancer than cervical cancer in the US.
- ~19,000: Oropharyngeal cases yearly (US diagnoses per year)
- 4:1: Male-to-female ratio (men affected far more)
- ~70%: HPV-attributable share (of oropharyngeal cancers)
- 50–60: Typical diagnosis age (years old at onset)
Oral sex transmission route
Oral HPV exposure seeds infection in tonsil crypts.
Overtaking cervical cancer
Oropharyngeal cases now exceed cervical cases nationally.
Late-stage detection
Throat tumors are often found only at advanced stage.
HPV Drives Anal Cancer In Both Sexes
Anal cancer incidence is rising in men and women alike.
- ~10,000: Anal cancer cases yearly (US diagnoses per year)
- ~90%: HPV-attributable share (of anal cancers)
- MSM, HIV+: Higher-risk group (elevated incidence groups)
- ~68%: Five-year survival (with early treatment)
Anal transformation zone
Anal squamocolumnar tissue behaves like cervical tissue.
Precancerous lesions
HPV causes AIN lesions that can progress to cancer.
No population screening
Most countries lack routine anal Pap testing.
Vulvar & Penile Cancer Risk
HPV causes genital cancers outside the cervix in both sexes.
- ~6,000: Vulvar cancer cases yearly (US diagnoses per year)
- ~2,100: Penile cancer cases yearly (US diagnoses per year)
- ~50%: HPV-attributable share (of these cancers)
- ↑ rising: Vulvar cases trend (especially in younger women)
Vulvar HPV pathway
Persistent HPV infection can progress to vulvar cancer.
Penile HPV pathway
HPV causes roughly half of all penile cancers.
Often overlooked risk
Genital cancers get less awareness than cervical cancer.
One Vaccine, Every Site Protected
HPV vaccination protects oropharyngeal, anal, vulvar and penile tissue together.
- 6: Cancer types prevented (cervical, oral, anal, genital)
- ~90%: Vaccine efficacy (against target HPV types)
- 11–12: Recommended age (years, before exposure)
- ~61%: US teen coverage (fully vaccinated, 2023)
Systemic antibody protection
Vaccination raises antibodies that protect every mucosal site.
Works for all sexes
Boys and girls both need vaccination for full protection.
Prevention beats screening
Vaccination prevents cancers with no screening test at all.